NAFDAC alerts Nigerians over circulation of counterfeit b...

Nigeria's pharmaceutical regulatory authority has sounded a critical alarm over the proliferation of counterfeit Phesgo 600mg, a dual-action breast cancer treatment manufactured by Roche. The alert, issued by NAFDAC (National Agency for Food and Drug Administration and Control), marks the latest in a troubling pattern of fake oncology drugs infiltrating African healthcare systems—a development with serious implications for European pharmaceutical companies and investors betting on African market expansion.

Phesgo represents a significant advancement in HER2-positive breast cancer treatment, combining pertuzumab and trastuzumab in a single subcutaneous injection. Its approval across African markets was viewed as a win for patient access to cutting-edge oncology. However, the emergence of counterfeit versions undermines this progress and reveals structural weaknesses in pharmaceutical supply chains across West Africa.

The counterfeit detection came through Lagos University Teaching Hospital, suggesting the fakes penetrated tertiary healthcare institutions—not just informal markets. This is particularly alarming because it indicates counterfeiters have become sophisticated enough to replicate packaging and labeling convincingly. For patients, exposure to fake oncology drugs isn't merely ineffective; it can accelerate disease progression while patients waste critical treatment windows and deplete financial resources.

From a market perspective, this crisis exposes a fundamental challenge facing pharmaceutical companies in Africa: the cost of maintaining secure distribution networks often exceeds profit margins on generic or mid-range drugs. Nigeria's pharmaceutical market was valued at approximately $3.2 billion in 2023, but counterfeits represent an estimated 10-15% of the market by some analyses. For specialty drugs like Phesgo, which retail at premium prices ($2,000-$3,000 per injection in developed markets), the profit incentive for counterfeiters is substantial.

European pharmaceutical giants—including Roche, Novartis, and GSK—have invested heavily in African expansion, betting on rising middle-class demand for advanced treatments. However, incidents like this underscore that market access alone doesn't guarantee market success. Supply chain integrity, regulatory enforcement, and authentication infrastructure remain underdeveloped across much of sub-Saharan Africa.

The NAFDAC warning also highlights regulatory capacity constraints. While NAFDAC has improved dramatically over the past decade, its ability to conduct field inspections, verify authenticity, and prosecute counterfeiters remains limited relative to the market's size. European investors considering partnerships with Nigerian distributors or healthcare providers must factor in elevated due diligence costs and supply chain verification expenses.

Interestingly, this crisis may accelerate adoption of blockchain-based drug authentication and serialization technologies—an emerging opportunity for European tech-pharmaceutical partnerships. Companies implementing QR-code verification, RFID tracking, or blockchain ledgers can differentiate themselves and build trust with both patients and healthcare providers.

For European investors, the lesson is clear: African pharmaceutical markets offer genuine growth, but success requires patient capital, robust compliance infrastructure, and acceptance of elevated operational costs. The counterfeit Phesgo incident is not a reason to retreat from Africa, but rather a signal to invest in supply chain security as a competitive advantage.